跳轉至內容
Merck
全部照片(4)

重要文件

AMAB91318

Sigma-Aldrich

Monoclonal Anti-CT83 antibody produced in mouse

enhanced validation

Prestige Antibodies® Powered by Atlas Antibodies, clone CL4762, purified immunoglobulin

同義詞:

CXorf61, FLJ20611, FLJ22913, KK-LC-1

登入查看組織和合約定價


About This Item

分類程式碼代碼:
12352203
人類蛋白質圖譜編號:
NACRES:
NA.41

生物源

mouse

品質等級

共軛

unconjugated

抗體表格

purified immunoglobulin

抗體產品種類

primary antibodies

無性繁殖

CL4762, monoclonal

產品線

Prestige Antibodies® Powered by Atlas Antibodies

形狀

buffered aqueous glycerol solution

物種活性

human

加強驗證

orthogonal RNAseq
Learn more about Antibody Enhanced Validation

技術

immunoblotting: 1 μg/mL
immunohistochemistry: 1:500-1:1000

同型

IgG1

免疫原序列

QRNTGEMSSNSTALALVRPSSSGLINSNTDNNLAVYDLSRDILNNFPHSIARQKRILVNLSMVENKLVELEHTLLSKGFRGASPHRKST

UniProt登錄號

運輸包裝

wet ice

儲存溫度

−20°C

目標翻譯後修改

unmodified

基因資訊

human ... CT83(203413)

一般說明

CT83 (cancer/testis antigen 83) is also called as CXorf61 and codes for a cancer/testis antigen that is located on human chromosome Xq22. The gene has 556 bp, including an open reading frame that has 113 amino acids. It is also termed as kita-kyushu lung cancer antigen 1 (KK-LC-1). CT83 is expressed in testis.

免疫原

cancer/testis antigen 83

應用

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies® protocols and other useful information.

生化/生理作用

CT83 (cancer/testis antigen 83) / CXorf61 has the ability to interact with tumor-specific cytotoxic T-cell lymphocytes in lung cancer cells and can be considered as a potential immunotherapy target. It also acts as a target for T cell based immunotherapy of triple-negative breast cancer.

特點和優勢

Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:
  • IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
  • Protein array of 364 human recombinant protein fragments.

聯結

Corresponding Antigen APREST83230

外觀

Solution in phosphate buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide.

法律資訊

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

未找到適合的產品?  

試用我們的產品選擇工具.

儲存類別代碼

10 - Combustible liquids

水污染物質分類(WGK)

WGK 1

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

未看到正確版本?

如果您需要一個特定的版本,您可以透過批號來尋找特定憑證。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

X-Linked Candidate Genes for a Ciliopathy-Like Disorder.
Pavey A R, et al.
Molecular Syndromology, 7(1), 37-42 (2016)
Correlation Between Expression of the Cancer/Testis Antigen KK-LC-1 and Helicobacter pylori Infection in Gastric Cancer.
Fukuyama T, et al.
In Vivo, 31(3), 403-407 (2017)
CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer.
Paret C, et al.
Oncotarget, 6(28), 25356-25356 (2015)
Takashi Fukuyama et al.
Cancer research, 66(9), 4922-4928 (2006-05-03)
The purpose of our present study is to identify a tumor-specific antigen capable of inducing a specific cellular immune response in lung cancer patients. We established a lung adenocarcinoma cell line, designated as F1121L, and induced tumor-specific CTL clone H1

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務